Abstract:
Objective: To observe the effect of Bifid Triple Viable Capsules Dissolving at Intestines combined with smecta in treatment of infantile diarrhea.
Methods: Totally 98 cases of children with diarrhea who accepted treatments in Gangtou Community Health Service Center of Central Hospital of Longhua District of Shenzhen City from September 2014 to January 2016 were randomly divided into observation group and control group, with 49 cases in each group. The control group received routine therapy, while the observation group, on the basis of the treatment for the control group, were treated with the Bifid Triple Viable Capsules Dissolving at Intestines combined with smecta. Then, after 1 week of treatment, the treatment effect, recovery time and adverse reaction of two groups of patients were observed.
Results: The total effective rate in the observation group was 91.8%(45/49), which was higher than the control group(75.5%, 37/49), and the difference was statistically significant(P<0.05). The recovery time of body temperature, stool frequency and stool character in the observation group was shorter than that in the control group, the difference being statistically significant(P<0.05). There was no serious adverse reaction in the two groups.
Conclusion: The clinical effects of Bifid Triple Viable Capsules Dissolving at Intestines combined with smecta in treatment of infantile diarrhea are significant, which can quickly control the disease, reduce the pain of children, and the safety is high, thus it can be used as the preferred drug treatment for children with diarrhea.

Key words: Diarrhea, Bifid Triple Viable Capsules Dissolving at Intestines, Smecta, Clinical effect, Children